Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - HC Wainwright increased their Q3 2025 earnings per share (EPS) estimates for Immix Biopharma in a report released on Wednesday, June 4th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.16) per share for the quarter, up from their previous forecast of ($0.22). HC Wainwright currently has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Immix Biopharma's current full-year earnings is ($0.87) per share. HC Wainwright also issued estimates for Immix Biopharma's Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.62) EPS.
Immix Biopharma Stock Up 8.2%
Shares of IMMX stock traded up $0.18 on Friday, hitting $2.37. The stock had a trading volume of 185,785 shares, compared to its average volume of 154,849. The business has a 50 day moving average price of $1.91 and a 200 day moving average price of $1.95. The company has a market cap of $66.07 million, a PE ratio of -2.79 and a beta of 0.31. Immix Biopharma has a one year low of $1.26 and a one year high of $3.00.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.09.
Hedge Funds Weigh In On Immix Biopharma
A hedge fund recently bought a new stake in Immix Biopharma stock. SBI Securities Co. Ltd. bought a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 17,500 shares of the company's stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned about 0.06% of Immix Biopharma at the end of the most recent reporting period. Institutional investors own 11.26% of the company's stock.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Recommended Stories
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
